InvestorsHub Logo
Followers 18
Posts 532
Boards Moderated 0
Alias Born 05/11/2011

Re: DimesForShares post# 234274

Friday, 01/21/2022 9:02:25 AM

Friday, January 21, 2022 9:02:25 AM

Post# of 278606

I also believe that proof of this method could be quite valuable for KBLB.



The proof of concept is already in the patent app if you know where to look.

The first image that you see is the plasmid map which shows each of the vectors used for this particular plasmid. You can clearly see that they used collagen as their donor sequence. That is as good of a protein to try as any for a proof of concept.

The company doesn't need to show every protein they plan on producing. The reality is there are thousands of protein targets. But they can mix and match the donor sequence with whichever protein target they want.

Wish I knew how far along they were in establishing the practicality of the method but we will only know more when KBLB reports further.



I think you may be confusing scientific publication writing and patent writing. With publications, it's important to lay out every part of your materials and methods, and more importantly, show results. In patent writing, you just need to cover your process and design to protect your invention.

The only thing you'll hear about this in the future is that Kraig Labs partnered with Company X to produce "protein Y" for $XXX. There is no more need for Kraig Labs to disclose anymore of this invention than they already have. It would be bad business to do so. If they were an academic lab that just wanted to be published, then maybe.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KBLB News